非酒精性脂肪性肝炎生物標誌物市場規模,份額和趨勢分析報告：按類型（血清,肝纖維化,細胞凋亡,氧化應激）,用戶（製藥和CRO,醫院）,地區預測2022-2030

非酒精性脂肪性肝炎生物標誌物的市場增長和趨勢

根據 Grand View Research, Inc. 的最新報告，到 2030 年，全球非酒精性脂肪性肝炎生物標誌物市場規模預計將達到 54 億美元，預測期內的複合年增長率為 23.6%。非酒精性脂肪性肝炎 (NASH) 生物標誌物市場的增長歸因於慢性病患病率上升以及對提供新診斷工具的需求不斷增加。非酒精性脂肪性肝炎 (NAFLD) 在患有某些疾病（如肥胖）或被認為與肥胖相關的疾病（如 2 型糖尿病）的人群中更為常見。據估計，三分之一到三分之二的 2 型糖尿病患者患有 NAFLD。

根據美國國立衛生研究院 2021 年 4 月的一項研究，高達 75% 的超重人群和超過 90% 的極度肥胖人群患有 NAFLD。越來越多的肥胖人口和不健康的飲食習慣為肝病的發展創造了有利的環境。因此，慢性肝病患病率的上升預計將刺激對 NASH 生物標誌物的需求。這一領域的持續研究活動可能會維持市場增長。

增長的一個主要驅動力是非酒精性脂肪性肝炎等慢性肝病發病率的增加以及開發早期檢測和診斷方法的需要。儘管缺乏用於診斷 NAFLD 的單一可靠的非侵入性程序，但非酒精性脂肪性肝炎生物標誌物市場具有顯著的增長潛力。另一個增長因素是對非侵入性診斷方法的需求不斷增長。由於其他診斷方法具有侵入性且價格昂貴，因此不適合患者使用。

此外，市場上的主要參與者正在專注於旨在提高公眾意識的合作夥伴關係，進一步促進市場的增長。例如，2022 年 6 月，Echosens 和諾和諾德宣佈建立合作夥伴關係，以提高對 NASH 的認識，並加快 Echosens 的 FibroScan 系統等非侵入性篩查方法的採用率。該夥伴關係的目標是到 2025 年將嚴重和晚期 NASH 的診斷率提高一倍。

診斷 NASH 的高成本是製約該市場增長的主要因素。例如，用於監測和診斷 NASH 的肝活檢是一種侵入性且昂貴的手術，費用高達 3500 美元。此外，FDA 等監管機構對生物標誌物的批准有嚴格的規定，這阻礙了行業的擴張。

非酒精性脂肪性肝炎生物標誌物市場報告要點

按類型劃分，血清生物標誌物領域在 NASH 生物標誌物市場中佔有最大份額，因為血清生物標誌物是最有效且使用最廣泛的診斷工具。

在終端用戶方面，由於對診斷肝病的非侵入性工具的高需求，預計製藥和 CRO 行業在預測期內增長最快

由於傳染病、心血管疾病和癌症的患病率上升，2021 年全球市場以北美為主

市場上的主要參與者正專注於專注於早期診斷的協作研究和合作夥伴關係，並提高人們對存在用於確定 NAFLD 和 NASH 的診斷工具的認識

Contents

第 1 章 NASH 生物標誌物市場：研究方法和範圍

• 調查方法
• 調查假設
• 資訊採購
  • 購買的數據庫
  • GVR 內部數據庫
  • 次要資訊
  • 初步調查
  • 初步調查的內容
• 資訊或數據分析
  • 數據分析模型
• 市場製定和驗證
• 模型詳細資訊
  • 商品流分析
    • 方法 1：商品流方法
  • 批量價格分析（模型 2）
    • 方法 2：體積分析
    • 收入建模
• 二級資訊列表
• 主要資訊列表

第 2 章 NASH 生物標誌物市場：執行摘要

• 市場概覽

第 3 章 NASH 生物標誌物市場：行業展望

• 市場系列展望
  • 母公司市場展望
• 描繪滲透率和增長前景
• 市場動態
  • 市場促進因素分析
    • 慢性肝病患病率上升
    • 對 NASH 生物標誌物的非侵入性診斷的需求不斷增加
    • 政府和私人組織增加對 NASH 生物標誌物療法研發的投資
  • 市場抑制因素分析
    • 與 NASH 藥物相關的副作用和風險
• 波特的五力分析
• SWOT 因素分析（政治和法律、經濟、技術）
• 監管框架
• 管道分析

第 4 章 NASH 生物標誌物市場：競爭格局

• 主要市場進入者的近期趨勢和影響分析
  • Ansoff Matrix
• Major deals &strategic alliances analysis
  • 合資企業
  • 許可和合作夥伴關係
  • 技術合作
• 公司/競爭對手分類
• 供應商情況
  • 主要分銷商和渠道合作夥伴列表
  • 主要客戶
• 上市公司
  • 公司市場分析
• 私人公司
  • 主要初創企業名單
  • 本地網絡地圖

第 5 章 NASH 生物標誌物市場：類型業務分析

• 定義和範圍
• 2021 年和 2030 年類型市場份額分析
• 全球 NASH 生物標誌物市場，按類型劃分，2018-2030 年
• 2018-2030 年市場規模和預測、趨勢分析
  • 血清生物標誌物
  • 肝纖維化生物標誌物
  • 細胞凋亡生物標誌物
  • 氧化應激生物標誌物
  • 其他

第 6 章 NASH 生物標誌物市場：最終用途業務分析

• 定義和範圍
• 2021 年和 2030 年終端用途市場份額分析
• 全球 NASH 生物標誌物市場，按最終用途分類，2018-2030 年
• 2018-2030 年市場規模和預測、趨勢分析
  • 製藥和 CRO 行業
  • 醫院
  • 診斷實驗室
  • 學術研究機構

第 7 章 NASH 生物標誌物市場：區域業務分析

• 定義和範圍
• 2021 年和 2030 年區域市場份額分析
• 區域市場儀表板
• 區域市場概況
• SWOT 分析，按因素（政治和法律、經濟和技術）
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 多邊環境協定
• 2021-2030 年市場規模、預測、趨勢分析
• 北美
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 法國
  • 意大利
  • 西班牙
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳大利亞
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 多邊環境協定
  • 南非
  • 沙特阿拉伯
  • 阿拉伯聯合酋長國

第 8 章 NASH 生物標誌物市場：公司概況

• 公司簡介
  • GENFIT
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Prometheus Laboratories
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • AstraZeneca
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Siemens Medical Solutions USA, Inc.
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Bristol-Myers Squibb Company
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • BioPredictive
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Quest Diagnostics
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Exalenz Bioscience Ltd
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Pfizer, Inc.
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措
  • Laboratory Corporation of America Holdings
    • 公司簡介
    • 財務業績
    • 產品基準
    • 戰略舉措

Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends:

The global non-alcoholic steatohepatitis biomarkers market size is expected to reach USD 5.4 billion by 2030, registering a CAGR of 23.6% during the forecast period, according to a new report by Grand View Research, Inc. The growth of the Non-alcoholic Steatohepatitis (NASH) biomarkers market is attributed to rising prevalence of chronic diseases and rising demand for providing novel diagnostic tools. Nonalcoholic Fatty Liver Disease (NAFLD) is more prevalent in people with specific diseases, such as obesity, and diseases that may be linked to obesity, including type 2 diabetes. One-third to two-thirds of people with type 2 diabetes are projected to have NAFLD.

According to April 2021 study by NIH, up to 75% of overweight individuals and more than 90% of individuals with extreme obesity have NAFLD. An increasing obese population and unhealthy food habits are creating a favorable environment for the development of liver disease. Therefore, the rising prevalence of chronic liver disease is expected to fuel the demand for NASH biomarkers. The ongoing research activities in this sector are likely to sustain the market growth.

The primary factor pertaining to growth is the increasing incidence of chronic liver illnesses like nonalcoholic steatohepatitis and the need to develop ways for their early detection and diagnosis. The market for non-alcoholic steatohepatitis biomarkers has enormous growth potential despite the lack of a single reliable non-invasive procedure to diagnose NAFLD. Another growth factor is the increasing demand for non-invasive diagnosis methods as other diagnostic procedures available are intrusive and expensive, thus they are not suitable for patients.

Moreover, major key players operating in the market are focusing on collaborations aiming toward expanding awareness among the population is further propelling the growth of market. For instance, in June 2022, Echosens and Novo Nordisk announced a partnership to increase awareness about NASH and accelerate the adoption rate of noninvasive screening methods such as Echosens' FibroScan system. The partnership strives to double the diagnosis rate of severe and advanced NASH by 2025.

The high cost of diagnosing NASH is a significant factor hindering the growth of the market. For instance, liver biopsy for NASH for monitoring and diagnosis of the disease can cost up to USD 3500 making it an invasive and expensive procedure. Furthermore, regulatory authorities such as the FDA have strict rules for biomarker approval, which is slowing industry expansion.

Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights:

• By type, the serum biomarkers segment held a larger share of the NASH biomarkers market since serum biomarkers are most effective and most widely used diagnosis tool

• By end-use, the pharma & CRO industry segment is expected to show the fastest growth over the forecast period due to the high demand for non-invasive tools for the diagnosis of liver diseases

• North America dominated the global market in 2021, owing to the rising prevalence of infectious diseases, cardiovascular diseases, and cancer

• Key players operating in the market are focusing on collaborations and partnerships focusing on expanding the awareness about early diagnosis and presence of diagnostic tools for determining NAFLD and NASH

Table of Contents

Chapter 1 NASH Biomarkers Market: Methodology and Scope

• 1.1 Research Methodology
• 1.2 Research Assumptions
  • 1.2.1 Estimates and forecast timeline
• 1.3 Information Procurement
  • 1.3.1 Purchased database
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
  • 1.3.5 Details of primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity flow analysis
    • 1.6.1.1 Approach 1: Commodity flow approach
  • 1.6.2 Volume price analysis (model 2)
    • 1.6.2.1 Approach 2: Volume price analysis
    • 1.6.2.2 Revenue modeling
• 1.7 List of Secondary Sources
• 1.8 List of Primary Sources

Chapter 2 NASH Biomarkers Market: Executive Summary

• 2.1 Market Summary

Chapter 3 NASH Biomarkers Market: Industry Outlook

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration & Growth Prospect Mapping
• 3.3 Market Dynamics
  • 3.3.1 Market Driver Analysis
    • 3.3.1.1 Rising prevalence of chronic liver diseases
    • 3.3.1.2 Increasing demand for non-invasive diagnostics for NASH biomarkers
    • 3.3.1.3 Rising investment by government and private organizations in R&D for NASH biomarkers therapeutics
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 Side-effects and risks associated with NASH therapeutics
• 3.4 Porter's Five Forces Analysis
• 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
• 3.6 Regulatory Framework
• 3.7 Pipeline Analysis

Chapter 4 NASH Biomarkers Market: Competitive Landscape

• 4.1 Recent developments & impact analysis, by key market participants
  • 4.1.1 Ansoff Matrix
• 4.2 Major deals & strategic alliances analysis
  • 4.2.1 Joint Ventures
  • 4.2.2 Licensing and Partnerships
  • 4.2.3 Technological Collaborations
• 4.3 Company/Competition Categorization
• 4.4 Vendor Landscape
  • 4.4.1 List Of Key Distributors and Channel Partners
  • 4.4.2 Key Customers
• 4.5 Public Companies
  • 4.5.1 Company Market Position Analysis
• 4.6 Private Companies
  • 4.6.1 List Of Key Emerging Companies
  • 4.6.2 Regional Network Map

Chapter 5 NASH Biomarkers Market: Type Business Analysis

• 5.1 Definition and Scope
• 5.2 Type Market Share Analysis, 2021 & 2030
• 5.3 Global NASH Biomarkers Market, By Type, 2018 To 2030
• 5.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 5.4.1 Serum Biomarkers
    • 5.4.1.1 Serum Biomarkers Market 2018 - 2030 (USD Million)
  • 5.4.2 Hepatic Fibrosis Biomarkers
    • 5.4.2.1 Hepatic Fibrosis Biomarkers Market, 2018 - 2030 (USD Million)
  • 5.4.3 Apoptosis Biomarkers
    • 5.4.3.1 Apoptosis Biomarkers Market, 2018 - 2030 (USD Million)
  • 5.4.4 Oxidative Stress Biomarkers
    • 5.4.4.1 Oxidative Stress Biomarkers Market, 2018 - 2030 (USD Million)
  • 5.4.5 Others
    • 5.4.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 NASH Biomarkers Market: End-Use Business Analysis

• 6.1 Definition and Scope
• 6.2 End-Use Market Share Analysis, 2021 & 2030
• 6.3 Global NASH Biomarkers Market, By End-Use, 2018 To 2030
• 6.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 6.4.1 Pharma & CRO Industry
    • 6.4.1.1 Pharma & CRO Industry Market 2018 - 2030 (USD Million)
  • 6.4.2 Hospitals
    • 6.4.2.1 Hospitals Market, 2018 - 2030 (USD Million)
  • 6.4.3 Diagnostic Labs
    • 6.4.3.1 Diagnostic Labs Market, 2018 - 2030 (USD Million)
  • 6.4.4 Academic Research Institutes
    • 6.4.4.1 Academic Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 7 NASH Biomarkers Market: Regional Business Analysis

• 7.1 Definition & Scope
• 7.2 Regional Market Share Analysis, 2021 & 2030
• 7.3 Regional Market Dashboard
• 7.4 Regional Market Snapshot
• 7.5 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 7.5.1 North America
  • 7.5.2 Europe
  • 7.5.3 Asia Pacific
  • 7.5.4 Latin America
  • 7.5.5 MEA
• 7.6 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
• 7.7 North America
  • 7.7.1 North America NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.7.2 U.S.
    • 7.7.2.1 U.S. NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.7.3 Canada
    • 7.7.3.1 Canada NASH Biomarkers Market, 2018 - 2030 (USD Million)
• 7.8 Europe
  • 7.8.1 Europe NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.8.2 U.K.
    • 7.8.2.1 U.K. NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.8.3 Germany
    • 7.8.3.1 Germany NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.8.4 France
    • 7.8.4.1 France NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.8.5 Italy
    • 7.8.5.1 Italy NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.8.6 Spain
    • 7.8.6.1 Spain NASH Biomarkers Market, 2018 - 2030 (USD Million)
• 7.9 Asia Pacific
  • 7.9.1 Asia Pacific NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.9.2 Japan
    • 7.9.2.1 Japan NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.9.3 China
    • 7.9.3.1 China NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.9.4 India
    • 7.9.4.1 India NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.9.5 Australia
    • 7.9.5.1 Australia NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.9.6 South Korea
    • 7.9.6.1 South Korea NASH Biomarkers Market, 2018 - 2030 (USD Million)
• 7.10 Latin America
  • 7.10.1 Latin America NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.10.2 Brazil
    • 7.10.2.1 Brazil NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.10.3 Mexico
    • 7.10.3.1 Mexico NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.10.4 Argentina
    • 7.10.4.1 Argentina NASH Biomarkers Market, 2018 - 2030 (USD Million)
• 7.11 MEA
  • 7.11.1 MEA NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.11.2 South Africa
    • 7.11.2.1 South Africa NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.11.3 Saudi Arabia
    • 7.11.3.1 Saudi Arabia NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.11.4 UAE
    • 7.11.4.1 UAE NASH Biomarkers Market, 2018 - 2030 (USD Million)

Chapter 8 NASH Biomarkers Market: Company Profiling

• 8.1 Company Profiles
  • 8.1.1. GENFIT
    • 8.1.1.1 Company overview
    • 8.1.1.2 Financial performance
    • 8.1.1.3 Product benchmarking
    • 8.1.1.4 Strategic initiatives
  • 8.1.2. Prometheus Laboratories
    • 8.1.2.1 Company overview
    • 8.1.2.2 Financial performance
    • 8.1.2.3 Product benchmarking
    • 8.1.2.4 Strategic initiatives
  • 8.1.3. AstraZeneca
    • 8.1.3.1 Company overview
    • 8.1.3.2 Financial performance
    • 8.1.3.3 Product benchmarking
    • 8.1.3.4 Strategic initiatives
  • 8.1.4. Siemens Medical Solutions USA, Inc.
    • 8.1.4.1 Company overview
    • 8.1.4.2 Financial performance
    • 8.1.4.3 Product benchmarking
    • 8.1.4.4 Strategic initiatives
  • 8.1.5. Bristol-Myers Squibb Company
    • 8.1.5.1 Company overview
    • 8.1.5.2 Financial performance
    • 8.1.5.3 Product benchmarking
    • 8.1.5.4 Strategic initiatives
  • 8.1.6. BioPredictive
    • 8.1.6.1 Company overview
    • 8.1.6.2 Financial performance
    • 8.1.6.3 Product benchmarking
    • 8.1.6.4 Strategic initiatives
  • 8.1.7. Quest Diagnostics
    • 8.1.7.1 Company overview
    • 8.1.7.2 Financial performance
    • 8.1.7.3 Product benchmarking
    • 8.1.7.4 Strategic initiatives
  • 8.1.8 Exalenz Bioscience Ltd
    • 8.1.8.1 Company overview
    • 8.1.8.2 Financial performance
    • 8.1.8.3 Product benchmarking
    • 8.1.8.4 Strategic initiatives
  • 8.1.9 Pfizer, Inc.
    • 8.1.9.1 Company overview
    • 8.1.9.2 Financial performance
    • 8.1.9.3 Product benchmarking
    • 8.1.9.4 Strategic initiatives
  • 8.1.10 Laboratory Corporation of America Holdings
    • 8.1.10.1 Company overview
    • 8.1.10.2 Financial performance
    • 8.1.10.3 Product benchmarking
    • 8.1.10.4 Strategic initiatives

List of Tables

• TABLE 1 List of Secondary Sources
• TABLE 2 List of Abbreviations
• TABLE 3 Regulatory Framework
• TABLE 4 Global NASH Biomarkers Market, By Region, 2018 - 2030 (USD Million)
• TABLE 5 Global NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 6 Global NASH Biomarkers Market, By End-use, 2018 - 2030 (USD Million)
• TABLE 7 North America NASH Biomarkers Market, By Country, 2018 - 2030 (USD Million)
• TABLE 8 North America NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 9 North America NASH Biomarkers Market, By End-use, 2018 - 2030 (USD Million)
• TABLE 10 U.S. NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 11 U.S. NASH Biomarkers Market, By End-use, 2018 - 2030 (USD Million)
• TABLE 12 Canada NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 13 Canada NASH Biomarkers Market, By End-use, 2018 - 2030 (USD Million)
• TABLE 14 Europe NASH Biomarkers Market, By Country, 2018 - 2030 (USD Million)
• TABLE 15 Europe NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 16 Europe NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 17 U.K. NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 18 U.K. NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 19 Germany NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 20 Germany NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 21 France NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 22 France NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 23 Spain NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 24 Spain NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 25 Italy NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 26 Italy NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 27 Asia Pacific NASH Biomarkers Market, By Country, 2018 - 2030 (USD Million)
• TABLE 28 Asia Pacific NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 29 Asia Pacific NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 30 China NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 31 China NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 32 Japan NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 33 Japan NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 34 India NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 35 India NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 36 South Korea NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 37 South Korea NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 38 Australia NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 39 Australia NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 40 Latin America NASH Biomarkers Market, By Country, 2018 - 2030 (USD Million)
• TABLE 41 Latin America NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 42 Latin America NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 43 Brazil NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 44 Brazil NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 45 Mexico NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 46 Mexico NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 47 Argentina NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 48 Argentina NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 49 MEA NASH Biomarkers Market, By Country, 2018 - 2030 (USD Million)
• TABLE 50 MEA NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 51 MEA NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 52 South Africa NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 53 South Africa NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 54 Saudi Arabia NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 55 Saudi Arabia NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 56 UAE NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 57 UAE NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)

List of Figures

• FIG. 1 Market Research Process
• FIG. 2 Information Procurement
• FIG. 3 Primary Research Pattern
• FIG. 4 Market Research Approaches
• FIG. 5 Value Chain-Based Sizing & Forecasting
• FIG. 6 Market Formulation & Validation
• FIG. 7 NASH Biomarkers Market Segmentation
• FIG. 8 Market Driver Relevance Analysis (Current & Future Impact)
• FIG. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• FIG. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• FIG. 11 Penetration & Growth Prospect Mapping
• FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• FIG. 13 Porter's Five Forces Analysis
• FIG. 14 Market Penetration & Growth Prospect Mapping
• FIG. 15 NASH Biomarkers Market: Type Movement Analysis
• FIG. 16 Serum biomarkers market, 2018 - 2030 (USD Million)
• FIG. 17 Hepatic fibrosis biomarkers market, 2018 - 2030 (USD Million)
• FIG. 18 Apoptosis biomarkers market, 2018 - 2030 (USD Million)
• FIG. 19 Oxidative stress biomarkers market, 2018 - 2030 (USD Million)
• FIG. 20 Others market, 2018 - 2030 (USD Million)
• FIG. 21 NASH Biomarkers Market: End-use Movement Analysis
• FIG. 22 Pharma & CRO Industry market, 2018 - 2030 (USD Million)
• FIG. 23 Hospitals market, 2018 - 2030 (USD Million)
• FIG. 24 Diagnostic Labs market, 2018 - 2030 (USD Million)
• FIG. 25 Academic Research Institutes market, 2018 - 2030 (USD Million)
• FIG. 26 Regional Marketplace: Key Takeaways
• FIG. 27 Regional Outlook, 2018 & 2030
• FIG. 28 Regional Market Dashboard
• FIG. 29 Regional Market Place: Key Takeaways
• FIG. 30 North America, SWOT Analysis
• FIG. 31 Europe, SWOT Analysis
• FIG. 32 Asia Pacific, SWOT Analysis
• FIG. 33 Latin America, SWOT Analysis
• FIG. 34 MEA, SWOT Analysis
• FIG. 35 North America
• FIG. 36 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 37 U.S.
• FIG. 38 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 39 Canada
• FIG. 40 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 41 Europe
• FIG. 42 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 43 UK
• FIG. 44 UK Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 45 Germany
• FIG. 46 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 47 France
• FIG. 48 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 49 Italy
• FIG. 50 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 51 Spain
• FIG. 52 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 53 Asia Pacific
• FIG. 54 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 55 Japan
• FIG. 56 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 57 China
• FIG. 58 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 59 India
• FIG. 60 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 61 Australia
• FIG. 62 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 63 South Korea
• FIG. 64 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 65 Latin America
• FIG. 66 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 67 Brazil
• FIG. 68 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 69 Mexico
• FIG. 70 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 71 Argentina
• FIG. 72 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 73 MEA
• FIG. 74 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 75 South Africa
• FIG. 76 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 77 Saudi Arabia
• FIG. 78 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 79 UAE
• FIG. 80 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 81 Strategy Mapping